In another clinical trial, NCT03190967, for HER2-positive breast cancer patients who developed brain metastases after local treatment, researchers explored the potential of oral TMZ combined with T-DM1 for systemic disease control as a secondary preventive strategy for these patients (Zimmer et al., 2020). This evidence concerns the gene ERBB2 and breast carcinoma.